Management of Osteoporosis: Who to Treat, What to Use, and for How Long?
Author:
Open Access
- 1 January 2013
- journal article
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 85 (4) , 364-373
Abstract
Kim SW. Korean J Med. 2013 Oct;85(4):364-373. http://dx.doi.org/10.3904/kjm.2013.85.4.364Keywords
This publication has 75 references indexed in Scilit:
- Effects of a single injection of teriparatide on bone turnover markers in postmenopausal womenOsteoporosis International, 2012
- The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 yearsJournal of Bone and Mineral Research, 2012
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extensionJournal of Bone and Mineral Research, 2011
- Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled studyOsteoporosis International, 2011
- Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal OsteoporosisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Zoledronic acid for the treatment and prevention of primary and secondary osteoporosisTherapeutic Advances in Musculoskeletal Disease, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Molecular and cellular mechanisms of the anabolic effect of intermittent PTHBone, 2007
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002